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Carotid artery stenting (CAS) is a less invasive alternative to ca-
rotid endarterectomy (CEA) for treatment of symptomatic carotid 
stenosis. The risk of peri-procedural cerebral ischemia is greater 
with CAS than with CEA.1 However, evidence on the occurrence of 
new hemorrhagic brain lesions after CAS or CEA is sparse. We 
aimed to assess the frequency of clinically silent brain hemor-
rhage on magnetic resonance imaging (MRI) after CAS and CEA 
in the MRI substudy of the International Carotid Stenting Study 
(ICSS), a registered clinical trial (RCTN25337470).
In ICSS, patients with symptomatic carotid stenosis were ran-
domized in a 1:1 ratio to CAS or CEA.2 In the ICSS-MRI substudy, 
patients were scanned with multi-modal MRI 1 to 7 days be-
fore, 1 to 3 days after and 30±3 days after revascularization, in-
cluding gradient-recalled echo (GRE) T2*-weighted MRI. The 
primary outcome of the present study was the presence of at 
least one new hemorrhagic brain lesion on the 30-day scan, de-
fined by any new signal hypointensity within the brain paren-
chyma on GRE T2* which was not present before treatment. 
Small, rounded hypointense lesions measuring ≤10 mm in diam-
eter were classified as cerebral microbleeds (CMBs).3 New hem-
orrhagic lesions on the 1-month follow-up scan occurring at 
the site of ischemic brain lesions seen on fluid-attenuated in-
version recovery sequences before treatment, or at the site of 
new diffusion-weighted imaging lesions in the scan done 1 to 3 
days after treatment, were classified as hemorrhagic transfor-
mations of ischemic infarcts, and were not counted as part of 
the primary outcome.
Details on the CAS and CEA procedures have been described 
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Table 1. Baseline characteristics, radiological, and clinical outcome events
Characteristic CAS (n=84) CEA (n=78) Total (n=162)
Age (yr) 70.4±8.9 69.4±8.5 69.9±8.7
Male sex 65 (77.4) 53 (67.9) 118 (72.8)
Vascular risk factors
History of hypertension 57 (68.0) 56 (72.0) 113 (70.0)
History of diabetes 18 (21.0) 19 (24.0) 37 (23.0)
History of hypercholesterolemia 54 (64.0) 54 (69.0) 108 (67.0)
Smoking (past or present) 66 (79.0) 54 (69.0) 120 (74.0)
Coronary heart disease 15 (18.0) 20 (26.0) 35 (22.0)
Peripheral artery disease 11 (13.0) 10 (13.0) 21 (13.0)
Blood pressure at randomization (mm Hg)
Systolic 158.6±28.3 158.2±25.1 158.4±26.8
Diastolic 81.9±14.0 81.9±11.9 81∙9±13.0
Mean 107.5±17.2 107.4±14.9 107.4±16.1
Blood pressure at hospital discharge (mm Hg)
Systolic 135.1±19.8 134.7±17.1 134.9±18.4
Diastolic 71.6±12.8 72.5±10.8 72.1±11.8
Mean 92.8±13.0 93.3±11.3 93.0±12.1
Blood pressure at 1 month follow-up (mm Hg)
Systolic 157.9±21.7 152.4±23.5 155.2±22.7
Diastolic 83.6±11.8 81.5±10.8 82.6±11.4
Mean 108.4±13.5 105.1±13.5 106.8±13.5
Most recent ipsilateral event*
Amaurosis fugax 21 (25.0) 14 (18.0) 35 (22.0)
Retinal stroke 5 (6.0) 1 (1.0) 6 (4.0)
Transient ischemic attack 24 (29.0) 30 (40.0) 54 (34.0)
Hemispheric stroke 34 (41.0) 31 (41.0) 65 (41.0)
Score on modified Rankin Scale at randomization
0 38 (45.0) 28 (36.0) 66 (41.0)
1 19 (23.0) 19 (24.0) 38 (24.0)
2 23 (27.0) 21 (27.0) 44 (27.0)
3 4 (5.0) 8 (10.0) 12 (7.0)
4 0 (0.0) 2 (3.0) 2 (1.0)
Degree of ipsilateral carotid stenosis at randomization†
Moderate (50%–69%) 13 (16.0) 7 (9.0) 20 (13.0)
Severe (70%–99%) 71 (85.0) 71 (91.0) 142 (88.0)
Contralateral severe carotid stenosis or occlusion 4 (5.0) 3 (4.0) 7 (4.0)
Baseline MRI characteristics‡
Presence of ischemic lesion on DWI before treatment 32 (38.0) 29 (37.0) 61 (38.0)
Presence of CMB on GRE T2* before treatment 16 (19.0) 12 (15.0) 28 (17.0)
Total ARWMC score 4 (2–7) 4 (2–8) 4 (2–7)
Radiological outcome events on 1-month MRI 
New hemorrhagic brain lesions 5 (6.0) 5 (6.4) 10 (6.2)
Ipsilateral carotid territory 4 ( 4 ( 8 (
Contralateral carotid or vertebrobasilar territory 1 ( 1 ( 1 (
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in detail before.2 In short, premedication for CAS was discre-
tionary, although the combination of aspirin and clopidogrel 
was recommended. Use of heparin during the procedure was 
mandatory. All CEA patients received antiplatelet therapy be-
fore and after the procedure. Assessment of MRI scans was 
done through consensus reading by two experienced readers 
who were blinded to the allocated treatment and clinical out-
come. In case of disagreement between the two, a third re-
viewer made the final decision. 
We analyzed all patients who received the randomly allocat-
ed treatment (CAS or CEA) and both the pre-treatment and 
30-day MRI scans including GRE T2* sequences in sufficient 
quality. We compared the proportion of patients with the pri-
mary outcome between the CAS and the CEA group using 
Fisher’s exact test. Binary logistic regression analysis was per-
formed to study the association between each of the clinical 
and radiological baseline variables (Table 1) and the primary 
outcome in both treatment groups combined. 
From 2005 to 2009, 260 patients were randomized at five 
ICSS-MRI substudy centers (CAS, n=129; CEA, n=131). Our 
Characteristic CAS (n=84) CEA (n=78) Total (n=162)
Clinical outcome events
Death 0 ( 0 ( 0 (
Any stroke 7 (8.3) 3 (3.8) 10 (6.2)
Ischemic 7 ( 3 ( 10 (
Hemorrhagic 0 ( 0 ( 0 (
Values are presented as mean± standard deviation, number (%), or median (interquartile range).
CAS, carotid artery stenting; CEA, carotid endarterectomy; MRI, magnetic resonance imaging; DWI, diffusion-weighted imaging; CMB, cerebral microbleed; 
GRE, gradient-recalled echo; ARWMC, age-related white matter changes.
*Type of qualifying event was not available in two patients in the CEA arm; †Degree of stenosis according to North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET) method; ‡On pre-treatment scan done within International Carotid Stenting Study (ICSS)-MRI Study.
Table 1. Continued
Figure 1. Study flow chart. Inclusion and reasons for exclusion of patients from analysis. CAS, carotid artery stenting; CEA, carotid endarterectomy; BMT, best 
medical therapy; MRI, magnetic resonance imaging; GRE, gradient-recalled echo; MI, myocardial infarction.
1 Received BMT only
129 Allocated CAS 131 Allocated CEA
84 Included in primary 
analysis
78 Included in primary 
analysis
97 CAS initiated 87 CEA initiated
94 CAS completed 87 CEA completed
260 Patients randomised
3 GRE not done
3 CAS aborted (1 received CEA, 2 received BMT 
only)
7 MRI contraindicated
1 No consent to MRI substudy
20 MRI scanner unavailable before treatment
1 Fatal peri-procedural MI
1 Fatal procedural stroke
1 Sudden cardiac death
2 In rehab or nursing home at 1 month
2 Withdrew consent for follow-up scan





84 Underwent follow-up 
scan
79 Underwent follow-up 
scan
4 GRE not done
1 Patient withdrew consent for treatment and 
received BMT only
1 Fatal peri-procedural stroke
1 No follow-up scan for medical reasons
6 MRI scanner unavailable at follow-up
1 Received CAS
5 Received BMT only
9 MRI contraindicated
2 No consent to MRI substudy
1 No pre-treatment scan for medical reasons
21 MRI scanner unavailable before treatment
1 GRE not done
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study population included 162 patients (CAS, n=84; CEA, 
n=78) who underwent treatment as randomly allocated and 
had complete MRI scans done before and 30 days after treat-
ment. Patient flow and reasons for exclusion from the present 
analysis are detailed in Figure 1. Patients were well matched in 
baseline characteristics (Table 1). Thirty-one patients were 
studied in 3 Tesla scanners (CAS, n=15; CEA, n=16) and 131 in 
1.5 Tesla scanners (CAS, n=69; CEA, n=62).
Seven patients in the CAS group (8.3%) and three patients in 
the CEA group (3.8%) suffered an ischemic stroke. All pre-ex-
isting hemorrhagic brain lesions seen on the pre-treatment 
scan were still visible on the 1-month follow-up scan. No clini-
cally manifest hemorrhagic strokes occurred. Hemorrhagic 
brain lesions, exclusively in the form of a single CMB, occurred 
in five patients in the CAS group (6.0%) and in five patients in 
the CEA group (6.4%, P=0.88). CMBs were located in the terri-
tory supplied by the treated carotid artery in eight patients and 
in the contralateral carotid territory in two patients. In the CAS 
group, two CMBs were located in deep structures (basal gan-
glia), two in the frontal lobe, and one in the temporal lobe. In 
the CEA group, two CMBs were located in deep structures (ex-
ternal capsule and deep/periventricular white matter), two in 
the frontal lobe, and one in the temporal lobe. None of the pa-
tients with CMBs had symptoms attributable to the lesion or 
cerebral hyperperfusion syndrome (CHS). CMBs were not asso-
ciated with any patient baseline characteristics including pres-
ence of CMBs before treatment, or baseline severity of white 
matter changes.
Our study has limitations. Due to the small number of pa-
tients exhibiting new hemorrhagic brain lesions on MRI after 
carotid revascularization, we are not able to draw any mean-
ingful conclusions on the association between hemorrhagic 
brain lesions and CHS, nor any of the assessed baseline risk 
factors including pre-existing CMBs. Second, no information 
was available on blood pressure values directly after CAS or 
CEA, or within a few days thereafter. In addition, only about 
one fifth of our patients were imaged on 3 Tesla scanners, and 
susceptibility weighted imaging sequences were not done. 
Therefore, we might have underestimated the true frequency 
of CMBs to some degree. 
In conclusion, we found that hemorrhagic brain lesions after 
carotid revascularization are rare, do not differ between CAS 
and CEA, and in our study exclusively occurred in the form of a 
single CMB, predominantly located in the territory supplied by 
the treated carotid artery. 
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